To include your compound in the COVID-19 Resource Center, submit it here.

Aldeyra reports Phase IIa data for dry eye candidate

Aldeyra Therapeutics Inc. (NASDAQ:ALDX) reported data from a Phase IIa trial showing that ADX-102 ophthalmic solution significantly improved multiple signs and symptoms of dry eye disease compared to baseline. The trial enrolled 51 patients

Read the full 347 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE